Bottom line
Is PJHRX a good fund? The bottom line
PJHRX is the Class R share class of PGIM Jennison Health Sciences Fund, an actively managed health care sector mutual fund from PGIM (Prudential).
Its expense ratio is 1.48% — about $148 a year on every $10,000 invested, more expensive than 80% of health care sector funds we track.
It returned +18.9% over one year, +6.3% a year over five years, +9.2% a year over ten (as of Dec 31, 2024, per its prospectus).
With $1.4 billion in net assets and 55 holdings, its largest position is Eli Lilly & Company (17.3%) and the top 10 make up 52.6% of the portfolio.
The closest lower-cost alternative we found is PRHSX (0.83%, 52% top-holdings overlap).
What stands out
- 5-year return beat 74% of category peers
- No front-end sales load
What to watch
- Expensive for its category (1.48%)
- Concentrated: top 10 holdings are 52.6% of assets
- 12b-1 marketing fee of 0.75% a year
Updated Nov 19, 2026
What PJHRX invests in
The investment objective of the Fund is long-term capital appreciation .
The Fund seeks investments whose prices will increase over time. The Fund normally invests at least 80% of its investable assets in equity and equity-related securities of health sciences companies, such as pharmaceutical companies, biotechnology companies, medical device manufacturers, healthcare service providers and health maintenance organizations (HMOs) and other companies that derive at least 50% of their assets, revenues or profits from operations in the Health Care sector. The group of industries in which the Fund concentrates its investments is known as its sector. The term investable assets refers to the Fund's net assets plus any borrowings for investment purposes. The Fund's investable assets will be less than its total assets to the extent that it has borrowed money for non-investment purposes, such as to meet anticipated redemptions. The Fund invests in securities of…
From the fund's prospectus (filed Jan 28, 2026).
PJHRX performance
| 1 yr | 5 yr | 10 yr | |
|---|---|---|---|
| PJHRX | +18.9% | +6.3% | +9.2% |
| Health Care Sector median | +14.5% | +4.2% | +7.9% |
Source: Fund prospectus, as of Dec 31, 2024
What PJHRX costs
On a $10,000 investment, PJHRX's 1.48% expense ratio costs about $148 a year. The prospectus estimates $2,020 in total costs over 10 years (assuming 5% annual returns). The median health care sector fund charges 0.96%.
PJHRX top 10 holdings
| # | Holding | % of fund |
|---|---|---|
| 1 | Eli Lilly & Company LLY | 17.35% |
| 2 | Merck & Company Inc MRK | 6.06% |
| 3 | Unitedhealth Group Inc UNH | 5.87% |
| 4 | Thermo Fisher Scientific Inc TMO | 4.56% |
| 5 | Argenx Se ARGX | 3.55% |
| 6 | Vertex Pharmaceuticals Inc VRTX | 3.37% |
| 7 | Danaher Corp DHR | 3.28% |
| 8 | Intuitive Surgical Inc ISRG | 3.07% |
| 9 | Lonza Group Ag LONN | 3.02% |
| 10 | Cvs Health Corp CVS | 2.52% |
Source: SEC Form N-PORT, period ended May 29, 2026
The top 10 make up 52.6% of the fund. See all top 25 holdings and asset mix →